A startup developing artificial intelligence technology for drug discovery is partnering with a large German drugmaker in connection with its most recent investment round. Salt Lake City-based ...
Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion Pharmaceuticals today announced the close of an additional $2.15M in funding, bringing its Series A round to a total of $15.05M for drug discovery at the ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...
Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify 100 ...
Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...
Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback